Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

Refinitiv閱讀少於1分鐘

Oncolytics Biotech Inc ONCY:

ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN FOR PELAREOREP IN FIRST-LINE PANCREATIC CANCER
ONCOLYTICS BIOTECH INC - TO LAUNCH IMMUNOTHERAPY TRIAL IN PANCREATIC CANCER IN 2026

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

登入或建立一個永久免費帳戶來閱讀此新聞